SCHEMBL6153790

SCHEMBL6153790

COC(=O)c1ccc(Nc2cccnc2)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.54
NPC1 O15118 2/20 0.54
MAPT P10636 2/20 0.54
TSHR P16473 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
GAA P10253 1/20 0.51
HSD17B10 Q99714 2/20 0.50
LMNA P02545 2/20 0.50
ALPL P05186 1/20 0.50
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
MKNK1 Q9BUB5 1/20 0.48
MKNK2 Q9HBH9 1/20 0.48
AHR P35869 1/20 0.48
ALDH1A1 P00352 1/20 0.47
NOTUM Q6P988 1/20 0.46
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153853 0.88 MKNK1 (0.63) KDM4ENPC1MAPTTSHRRAB9A
SCHEMBL12893519 0.83 SMN1; SMN2 (0.50) KDM4EMAPTRAB9ASMN1; SMN2LMNA
SCHEMBL2907654 0.80 RECQL (0.59) KDM4EMAPTTSHRSMN1; SMN2GAA
SCHEMBL6154242 0.76 NPC1 (0.52) KDM4ENPC1RAB9ASMN1; SMN2GAA
SCHEMBL15131717 0.76 KDM4E (0.59) KDM4ENPC1MAPTTSHRRAB9A
SCHEMBL29110310 0.75 GRIK1 (0.56) KDM4EMAPTRAB9AHSD17B10LMNA
SCHEMBL21056875 0.75 KDM4E (0.61) KDM4EMAPTTSHRRAB9AGAA
SCHEMBL22160131 0.75 KDM4E (0.73) KDM4EMAPTTSHRHSD17B10POLB
SCHEMBL5915825 0.75 RAB9A (0.48) KDM4ENPC1MAPTRAB9AGAA
SCHEMBL10642215 0.74 KDM4E (0.56) KDM4ENPC1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 KDM4E 2017/4885NPC1 116/4885MAPT 4237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.